FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to oncology, and can be used for treating breast cancer (BC). According to the invention, the inventive method consists in introducing an estrogen-positive alpha to a subject suffering from BC, which is drug-resistant and/or contains a mutant alpha estrogen receptor, a therapeutically effective quantity of a combination of everolimus and RAD1901.
EFFECT: use of the invention enables inhibiting the growth and achieving regression of the tumor by the synergistic action of the combination.
18 cl, 36 dwg, 14 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATING CANCER | 2016 |
|
RU2747228C2 |
| METHODS OF TREATING CANCER | 2016 |
|
RU2737496C2 |
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
| METHODS FOR TREATMENT OF OVARIAN CANCER | 2017 |
|
RU2772432C2 |
| METHODS OF TREATING CANCER ON MODELS HAVING ESR1 MUTATIONS | 2019 |
|
RU2822195C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| COMPLEX THERAPY FOR CANCER TREATMENT | 2018 |
|
RU2810487C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
